Julie D. Constable represents public and private companies in the pharmaceutical, biotechnology, medical device and health care industries at all stages of development. Julie regularly advises her clients in a variety of transactions, including public and private securities offerings, mergers and acquisitions, license and collaboration agreements, securities law compliance and general corporate matters.
Prior to joining Ropes & Gray, Julie worked in the health care industry specializing in policy matters related to access, cost containment, quality and safety. Additionally, she published articles in a variety of news organizations, including The Boston Globe, The New York Times and CNN.com. Julie holds a M.S. in Health Policy and Management from the Harvard School of Public Health.
- JD, cum laude, Georgetown University Law Center, 2012; Georgetown Law Journal ; Legal Research and Writing Fellow; Barrister’s Council, Alternative Dispute Resolution Division
- MS (Health Policy and Management), Harvard School of Public Health, 2009
- BS (Print Journalism), summa cum laude, Emerson College, 2005
ADMISSIONS : Massachusetts, 2012
MEMBERSHIP & AFFILIATIONS : Boston Bar Association
- Served as in-house corporate counsel on six-month secondment to Waters Corporation, advising on strategic partnerships, including negotiating technology licensing arrangements and manufacturing, supply and distribution agreements with business partners.
- Represented Mersana Therapeutics in its $75 million initial public offering.
- Represented Kastle Therapeutics in its acquisition of global rights to develop and commercialize KYNAMRO® from Ionis Pharmaceuticals for consideration totaling up to $95 million.
- Represented Aegerion Pharmaceuticals, Inc. in its acquisition of the commercial drug Myalept from AstraZeneca for a $325 million upfront payment.
- Represented Genocea Biosciences, Inc. in its $66 million initial public offering and $51.7 million follow-on public offering.
- Represented TPG Biotech and Longitude Venture Partners in a $31.5 million series B preferred stock financing of Rapid Micro Biosystems.
Rate : $$$